Literature DB >> 31132073

Fully Human Tumor-based Matrix in Three-dimensional Spheroid Invasion Assay.

Erika Naakka1, Katja Tuomainen1, Henrik Wistrand1, Miila Palkama1, Ilida Suleymanova1, Ahmed Al-Samadi1, Tuula Salo2.   

Abstract

Two-dimensional cell culture-based assays are commonly used in in vitro cancer research. However, they lack several basic elements that form the tumor microenvironment. To obtain more reliable in vitro results, several three-dimensional (3D) cell culture assays have been introduced. These assays allow cancer cells to interact with the extracellular matrix. This interaction affects cell behavior, such as proliferation and invasion, as well as cell morphology. Additionally, this interaction could induce or suppress the expression of several pro- and anti-tumorigenic molecules. Spheroid invasion assay was developed to provide a suitable 3D in vitro method to study cancer cell invasion. Currently, animal-derived matrices, such as mouse sarcoma-derived matrix (MSDM) and rat tail type I collagen, are mainly used in the spheroid invasion assays. Taking into consideration the differences between the human tumor microenvironment and animal-derived matrices, a human myoma-derived matrix (HMDM) was developed from benign uterus leiomyoma tissue. It has been shown that HMDM induces migration and invasion of carcinoma cells better than MSDM. This protocol provided a simple, reproducible, and reliable 3D human tumor-based spheroid invasion assay using the HMDM/fibrin matrix. It also includes detailed instructions on imaging and analysis. The spheroids grow in a U-shaped ultra-low attachment plate within the HMDM/fibrin matrix and invade through it. The invasion is daily imaged, measured, and analyzed using ilastik and Fiji ImageJ software. The assay platform was demonstrated using human laryngeal primary and metastatic squamous cell carcinoma cell lines. However, the protocol is suitable also for other solid cancer cell lines.

Entities:  

Mesh:

Year:  2019        PMID: 31132073     DOI: 10.3791/59567

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  5 in total

1.  Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment.

Authors:  Ewelina Gumbarewicz; Przemko Tylżanowski; Jarogniew Łuszczki; Joanna Kałafut; Arkadiusz Czerwonka; Justyna Szumiło; Anna Wawruszak; Krzysztof Kupisz; Krzysztof Polberg; Jolanta Smok-Kalwat; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

2.  Human myoma tissue-based extracellular matrix models for testing the effects of irradiation on the HPV positive cells.

Authors:  Heidi Tuominen; Ahmed Al-Samadi; Tuula Salo; Jaana Rautava
Journal:  Virol J       Date:  2020-06-30       Impact factor: 4.099

3.  miR-22 and miR-205 Drive Tumor Aggressiveness of Mucoepidermoid Carcinomas of Salivary Glands.

Authors:  Erika Naakka; Mateus Camargo Barros-Filho; Shady Adnan-Awad; Ahmed Al-Samadi; Fábio Albuquerque Marchi; Hellen Kuasne; Katja Korelin; Ilida Suleymanova; Amy Louise Brown; Cristovam Scapulatempo-Neto; Silvia Vanessa Lourenço; Rogério Moraes Castilho; Luiz Paulo Kowalski; Antti Mäkitie; Vera Cavalcanti Araújo; Ilmo Leivo; Silvia Regina Rogatto; Tuula Salo; Fabricio Passador-Santos
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

Review 4.  In vitro models as tools for screening treatment options of head and neck cancer.

Authors:  Barbara Seliger; Ahmed Al-Samadi; Bo Yang; Tuula Salo; Claudia Wickenhauser
Journal:  Front Med (Lausanne)       Date:  2022-09-07

5.  Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing.

Authors:  Katja Tuomainen; Ahmed Al-Samadi; Swapnil Potdar; Laura Turunen; Minna Turunen; Piia-Riitta Karhemo; Paula Bergman; Maija Risteli; Pirjo Åström; Riia Tiikkaja; Reidar Grenman; Krister Wennerberg; Outi Monni; Tuula Salo
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.